nach oben

Erschienen in:

28.08.2017 | Review

Psychometric validation of the SF-36^® Health Survey in ulcerative colitis: results from a systematic literature review

verfasst von: Aaron Yarlas, Martha Bayliss, Joseph C. Cappelleri, Stephen Maher, Andrew G. Bushmakin, Lea Ann Chen, Alireza Manuchehri, Paul Healey

Erschienen in: Quality of Life Research | Ausgabe 2/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To conduct a systematic literature review of the reliability, construct validity, and responsiveness of the SF-36^® Health Survey (SF-36) in patients with ulcerative colitis (UC).

Methods

We performed a systematic search of electronic medical databases to identify published peer-reviewed studies which reported scores from the eight scales and/or two summary measures of the SF-36 collected from adult patients with UC. Study findings relevant to reliability, construct validity, and responsiveness were reviewed.

Results

Data were extracted and summarized from 43 articles meeting inclusion criteria. Convergent validity was supported by findings that 83% (197/236) of correlations between SF-36 scales and measures of disease symptoms, disease activity, and functioning exceeded the prespecified threshold (r ≥ |0.40|). Known-groups validity was supported by findings of clinically meaningful differences in SF-36 scores between subgroups of patients when classified by disease activity (i.e., active versus inactive), symptom status, and comorbidity status. Responsiveness was supported by findings of clinically meaningful changes in SF-36 scores following treatment in non-comparative trials, and by meaningfully larger improvements in SF-36 scores in treatment arms relative to controls in randomized controlled trials. The sole study of SF-36 reliability found evidence supporting internal consistency (Cronbach’s α ≥ 0.70) for all SF-36 scales and test–retest reliability (intraclass correlation coefficient ≥0.70) for six of eight scales.

Conclusions

Evidence from this systematic literature review indicates that the SF-36 is reliable, valid, and responsive when used with UC patients, supporting the inclusion of the SF-36 as an endpoint in clinical trials for this patient population.

Nur mit Berechtigung zugänglich

Shivashankar, R., Tremaine, W., Harmsen, S., Zinsmeister, A., & Loftus, E. (2014). Updated incidence and prevalence of Crohn’s disease and ulcerative colitis in Olmsted County, Minnesota (1970-2010). In ACG 2014 Annual Scientific Meeting Abstracts. Philadelphia, PA: American College of Gastroenterology.

Travis, S. P. L., Higgins, P. D. R., Orchard, T., van der Woude, C. J., Panaccione, R., Bitton, A., et al. (2011). Review article: Defining remission in ulcerative colitis. Alimentary Pharmacology & Therapeutics, 34, 113–124. doi:10.1111/j.1365-2036.2011.04701.x.CrossRef

Walsh, A. J., Bryant, R. V., & Travis, S. P. L. (2016). Current best practice for disease activity assessment in IBD. Nature Reviews Gastroenterology & Hepatology, 13, 567–579. doi:10.1038/nrgastro.2016.128.CrossRef

Mosli, M. H., Feagan, B. G., Sandborn, W. J., D’haens, G., Behling, C., Kaplan, K., et al. (2014). Histologic evaluation of ulcerative colitis: A systematic review of disease activity indices. Inflammatory Bowel Diseases, 20, 564–575. doi:10.1097/01.MIB.0000437986.00190.71.CrossRefPubMed

Bressler, B., Marshall, J. K., Bernstein, C. N., Bitton, A., Jones, J., Leontiadis, G. I., et al. (2015). Clinical practice guidelines for the medical management of nonhospitalized ulcerative colitis: The Toronto consensus. Gastroenterology, 148(1035–1058), e3. doi:10.1053/j.gastro.2015.03.001.

D’Haens, G., Sandborn, W. J., Feagan, B. G., Geboes, K., Hanauer, S. B., Irvine, E. J., et al. (2007). A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology, 132, 763–786.CrossRefPubMed

EMA. (2014). Reflection Paper on the use of patient reported outcome (PRO) measures in oncology studies [Draft]: European Medicines Agency, Oncology Working Party. Doc. Ref. EMA/CHMP/292464/2014; .

U. S. Food and Drug Administration. (2009). Guidance for industry: Patient-reported outcome measures: Use in medical product development to support labeling claims.

Medical Research Council (MRC). (2009). Patient Reported Outcome Measures (PROMs): Identifying UK research priorities. London: MRC.

10.

Panes, J., Su, C., Bushmakin, A. G., Cappelleri, J. C., Mamolo, C., & Healey, P. (2015). Randomized trial of tofacitinib in active ulcerative colitis: Analysis of efficacy based on patient-reported outcomes. BMC Gastroenterology, 15, 14. doi:10.1186/s12876-015-0239-9.CrossRefPubMedPubMedCentral

11.

Pallis, A. G., Vlachonikolis, I. G., & Mouzas, I. A. (2002). Assessing health-related quality of life in patients with inflammatory bowel disease, in Crete, Greece. BMC Gastroenterology, 2, 1.CrossRefPubMedPubMedCentral

12.

Solomon, D., Yarlas, A., Hodgkins, P., Karlstadt, R., Yen, L., & Kane, S. (2012). The impact of MMX mesalazine on disease-specific health-related quality of life in ulcerative colitis patients. Alimentary Pharmacology & Therapeutics, 35, 1386–1396. doi:10.1111/j.1365-2036.2012.05107.x.CrossRef

13.

Yarlas, A., Yen, L., & Hodgkins, P. (2015). The relationship among multiple patient-reported outcomes measures for patients with ulcerative colitis receiving treatment with MMX (R) formulated delayed-release mesalamine. Quality of Life Research, 24, 671–683. doi:10.1007/s11136-014-0797-2.CrossRefPubMed

14.

Theede, K., Kiszka-Kanowitz, M., Nordgaard-Lassen, I., & Mertz, Nielsen A. (2015). The impact of endoscopic inflammation and mucosal healing on health-related quality of life in ulcerative colitis patients. Journal of Crohns and Colitis, 9, 625–632. doi:10.1093/ecco-jcc/jjv081.CrossRef

15.

Casellas, F., Barreiro de Acosta, M., Iglesias, M., Robles, V., Nos, P., Aguas, M., et al. (2012). Mucosal healing restores normal health and quality of life in patients with inflammatory bowel disease. European Journal of Gastroenterology and Hepatology, 24, 762–769. doi:10.1097/MEG.0b013e32835414b2.CrossRefPubMed

16.

Casellas, F., Alcala, M., Prieto, L., Miro, J. A., & Malagelada, J. (2004). Assessment of the influence of disease activity on the quality of life of patients with inflammatory bowel disease using a short questionnaire. American Journal of Gastroenterology, 99, 457–461. doi:10.1111/j.1572-0241.2004.04071.x.CrossRefPubMed

17.

Gibson, P. R., Vaizey, C., Black, C. M., Nicholls, R., Weston, A. R., Bampton, P., et al. (2014). Relationship between disease severity and quality of life and assessment of health care utilization and cost for ulcerative colitis in Australia: A cross-sectional, observational study. Journal of Crohns and Colitis, 8, 598–606. doi:10.1016/j.crohns.2013.11.017.CrossRef

18.

Han, S. W., McColl, E., Barton, J. R., James, P., Steen, I. N., & Welfare, M. R. (2005). Predictors of quality of life in ulcerative colitis: The importance of symptoms and illness representations. Inflammatory Bowel Diseases, 11, 24–34.CrossRefPubMed

19.

Jharap, B., Sandborn, W. J., Reinisch, W., D’Haens, G., Robinson, A. M., Wang, W., et al. (2015). Randomised clinical study: discrepancies between patient-reported outcomes and endoscopic appearance in moderate to severe ulcerative colitis. Alimentary Pharmacology & Therapeutics, 42, 1082–1092. doi:10.1111/apt.13387.CrossRef

20.

Kantz, M. E., Harris, W. J., Levitsky, K., Ware Jr, J. E., & Davies, A. R. (1992). Methods for assessing condition-specific and generic functional status outcomes after total knee replacement. Medical Care, 30, MS240–MS252.CrossRefPubMed

21.

Hawker, G., Melfi, C., Paul, J., Green, R., & Bombardier, C. (1995). Comparison of a generic (SF-36) and a disease specific (WOMAC) (Western Ontario and McMaster Universities Osteoarthritis Index) instrument in the measurement of outcomes after knee replacement surgery. Journal of Rheumatology, 22, 1193–1196.PubMed

22.

Bombardier, C., Melfi, C. A., Paul, J., Green, R., Hawker, G., Wright, J., et al. (1995). Comparison of a generic and a disease-specific measure of pain and physical function after knee replacement surgery. Medical Care, 33, AS131–AS144.PubMed

23.

Ware, J. E. (2000). Editorial: Using generic measures of functional health and well-being to increase understanding of disease burden. Spine (Phila Pa 1976), 25, 1467. doi:10.1097/00007632-200006150-00002.CrossRef

24.

Strand, V., Boers, M., Idzerda, L., Kirwan, J. R., Kvien, T. K., Tugwell, P. S., et al. (2011). It’s good to feel better but it’s better to feel good and even better to feel good as soon as possible for as long as possible. Response criteria and the importance of change at OMERACT 10. Journal of Rheumatology, 38, 1720–1727. doi:10.3899/jrheum.110392.CrossRefPubMed

25.

Guyatt, G., Mitchell, A., Irvine, E. J., Singer, J., Williams, N., Goodacre, R., et al. (1989). A new measure of health status for clinical trials in inflammatory bowel disease. Gastroenterology, 96, 804–810.CrossRefPubMed

26.

McColl, E., Han, S. W., Barton, J. R., & Welfare, M. R. (2004). A comparison of the discriminatory power of the Inflammatory Bowel Disease Questionnaire and the SF-36 in people with ulcerative colitis. Quality of Life Research, 13, 805–811.CrossRefPubMed

27.

McHorney, C. A., Ware, J. E., Jr., & Raczek, A. E. (1993). The MOS 36-Item Short-Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Medical Care, 31, 247–263.CrossRefPubMed

28.

Ware, J. E., Jr., & Sherbourne, C. D. (1992). The MOS 36-item Short-Form Health Survey (SF-36). I. Conceptual framework and item selection. Medical Care, 30, 473–483.CrossRefPubMed

29.

Ware, J. E., Jr. (2000). SF-36 health survey update. Spine (Phila Pa 1976), 25, 3130–3139.CrossRef

30.

Jaeschke, R., Singer, J., & Guyatt, G. H. (1989). Measurement of health status. Ascertaining the minimal clinically important difference. Controlled Clinical Trials, 10, 407–415.CrossRefPubMed

31.

Ware, J. E., Jr., Kosinski, M., Bjorner, J. B., Turner-Bowker, D. M., Gandek, B., & Maruish, M. E. (2007). User’s manual for the SF-36v2 Health Survey (2nd ed.). Lincoln, RI: QualityMetric Incorporated.

32.

Moher, D., Liberati, A., Tetzlaff, J., & Altman, D. G. (2009). Preferred reporting items for systematic reviews and meta-analyses: The PRISMA Statement. Open Medicine, 3, e123–e130. doi:10.1371/journal.pmed.1000097.PubMedPubMedCentral

33.

Nunnally, J., & Bernstein, L. (1994). Psychometric theory. New York: McGraw-Hill.

34.

Terwee, C. B., Bot, S. D., de Boer, M. R., van der Windt, D. A. W. M., Knol, D. L., Dekker, J., et al. (2007). Quality criteria were proposed for measurement properties of health status questionnaires. Journal of Clinical Epidemiology, 60, 34–42. doi:10.1016/j.jclinepi.2006.03.012.CrossRefPubMed

35.

Cappelleri, J. C., Zou, K. H., Bushmakin, A. G., Alvir, J. M., Alemayehu, D., & Symonds, T. (2013). Patient-reported outcomes: Measurement, implementation and interpretation. Boca Raton, FL: Chapman & Hall/CRC Press.

36.

Schroeder, K. W., Tremaine, W. J., & Ilstrup, D. M. (1987). Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. New England Journal of Medicine, 317, 1625–1629. doi:10.1056/NEJM198712243172603.CrossRefPubMed

37.

Bernklev, T., Jahnsen, J., Lygren, I., Henriksen, M., Vatn, M., & Moum, B. (2005). Health-related quality of life in patients with inflammatory bowel disease measured with the short form-36: Psychometric assessments and a comparison with general population norms. Inflammatory Bowel Diseases, 11, 909–918.CrossRefPubMed

38.

Russel, M. G., Pastoor, C. J., Brandon, S., Rijken, J., Engels, L. G., van der Heijde, D. M., et al. (1997). Validation of the Dutch translation of the Inflammatory Bowel Disease Questionnaire (IBDQ): A health-related quality of life questionnaire in inflammatory bowel disease. Digestion, 58, 282–288.CrossRefPubMed

39.

Verissimo, R. (2008). Quality of life in inflammatory bowel disease: Psychometric evaluation of an IBDQ cross-culturally adapted version. Journal Gastrointestinal and Liver Diseases, 17, 439–444.

40.

Leong, R. W. L., Lee, Y. T., Ching, J. Y. L., & Sung, J. J. Y. (2003). Quality of life in Chinese patients with inflammatory bowel disease: Validation of the Chinese translation of the Inflammatory Bowel Disease Questionnaire. Alimentary Pharmacology & Therapeutics, 17, 711–718.CrossRef

41.

Pallis, A. G., Vlachonikolis, I. G., & Mouzas, I. A. (2001). Quality of life of Greek patients with inflammatory bowel disease. Validation of the Greek translation of the inflammatory bowel disease questionnaire. Digestion, 63, 240–246.CrossRefPubMed

42.

Ren, W. H., Lai, M., Chen, Y., Irvine, E. J., & Zhou, Y. X. (2007). Validation of the mainland Chinese version of the Inflammatory Bowel Disease Questionnaire (IBDQ) for ulcerative colitis and Crohn’s disease. Inflammatory Bowel Diseases, 13, 903–910. doi:10.1002/ibd.20128.CrossRefPubMed

43.

Xu, J., Lin, H., Feng, X., Tang, M., Shen, J., & Ran, Z. (2014). Different therapeutic approaches on quality of life in patients with inflammatory bowel disease. BMC Gastroenterology, 14, 199. doi:10.1186/s12876-014-0199-5.CrossRefPubMedPubMedCentral

44.

Hjortswang, H., Jarnerot, G., Curman, B., Sandberg-Gertzen, H., Tysk, C., Blomberg, B., et al. (2001). Validation of the inflammatory bowel disease questionnaire in Swedish patients with ulcerative colitis. Scandinavian Journal of Gastroenterology, 36, 77–85.CrossRefPubMed

45.

Han, S. W., McColl, E., Steen, N., Barton, J. R., & Welfare, M. R. (1998). The inflammatory bowel disease questionnaire: A valid and reliable measure in ulcerative colitis patients in the North East of England. Scandinavian Journal of Gastroenterology, 33, 961–966.CrossRefPubMed

46.

Hauser, W., Dietz, N., Grandt, D., Steder-Neukamm, U., Janke, K., Stein, U., et al. (2004). Validation of the inflammatory bowel disease questionnaire IBDQ-D, German version, for patients with ileal pouch anal anastomosis for ulcerative colitis. Zeitschrift fur Gastroenterologie, 42, 131–139. doi:10.1055/s-2004-812835.CrossRefPubMed

47.

Ruan, J., Chen, Y., & Zhou, Y. (2017). Development and validation of a questionnaire to assess the quality of life in patients with Inflammatory bowel disease in Mainland China. Inflammatory Bowel Diseases, 23, 431–439. doi:10.1097/MIB.0000000000001024.CrossRefPubMed

48.

Drossman, D. A., Leserman, J., Li, Z. M., Mitchell, C. M., Zagami, E. A., & Patrick, D. L. (1991). The rating form of IBD patient concerns: A new measure of health status. Psychosomatic Medicine, 53, 701–712.CrossRefPubMed

49.

Jelsness-Jorgensen, L., Moum, B., & Bernklev, T. (2011). Worries and concerns among inflammatory bowel disease patients followed prospectively over one year. Gastroenterology Research and Practice, 2011, 492034. doi:10.1155/2011/492034.CrossRefPubMedPubMedCentral

50.

Hjortswang, H., Strom, M., Almeida, R. T., & Almer, S. (1997). Evaluation of the RFIPC, a disease-specific health-related quality of life questionnaire, in Swedish patients with ulcerative colitis. Scandinavian Journal of Gastroenterology, 32, 1235–1240.CrossRefPubMed

51.

Jelsness-Jorgensen, L., Bernklev, T., Henriksen, M., Torp, R., & Moum, B. (2012). Chronic fatigue is associated with increased disease-related worries and concerns in inflammatory bowel disease. World Journal of Gastroenterology, 18, 445–452. doi:10.3748/wjg.v18.i5.445.CrossRefPubMedPubMedCentral

52.

Hjortswang, H., Jarnerot, G., Curman, B., Sandberg-Gertzen, H., Tysk, C., Blomberg, B., et al. (2006). The Short Health Scale: A valid measure of subjective health in ulcerative colitis. Scandinavian Journal of Gastroenterology, 41, 1196–1203. doi:10.1080/00365520600610618.CrossRefPubMed

53.

Jelsness-Jorgensen, L., Bernklev, T., & Moum, B. (2012). Quality of life in patients with inflammatory bowel disease: Translation, validity, reliability and sensitivity to change of the Norwegian version of the short health scale (SHS). Quality of Life Research, 21, 1671–1676. doi:10.1007/s11136-011-0081-7.CrossRefPubMed

54.

Cleeland, C. S., & Ryan, K. M. (1994). Pain assessment: Global use of the Brief Pain Inventory. Annals of the Academy of Medicine Singapore, 23, 129–138.

55.

Osborne, T. L., Raichle, K. A., Jensen, M. P., Ehde, D. M., & Kraft, G. (2006). The reliability and validity of pain interference measures in persons with multiple sclerosis. Journal of Pain and Symptom Management, 32, 217–229. doi:10.1016/j.jpainsymman.2006.03.008.CrossRefPubMed

56.

Zelman, D. C., Gore, M., Dukes, E., Tai, K., & Brandenburg, N. (2005). Validation of a modified version of the brief pain inventory for painful diabetic peripheral neuropathy. Journal of Pain and Symptom Management, 29, 401–410. doi:10.1016/j.jpainsymman.2004.06.018.CrossRefPubMed

57.

Keller, S., Bann, C. M., Dodd, S. L., Schein, J., Mendoza, T. R., & Cleeland, C. S. (2004). Validity of the brief pain inventory for use in documenting the outcomes of patients with noncancer pain. Clinical Journal of Pain, 20, 309–318.CrossRefPubMed

58.

Mendoza, T., Mayne, T., Rublee, D., & Cleeland, C. (2006). Reliability and validity of a modified Brief Pain Inventory short form in patients with osteoarthritis. European Journal of Pain, 10, 353–361. doi:10.1016/j.ejpain.2005.06.002.CrossRefPubMed

59.

Jelsness-Jorgensen, L., Moum, B., Grimstad, T., Jahnsen, J., Opheim, R., Prytz Berset, I., et al. (2016). Validity, reliability, and responsiveness of the brief pain inventory in inflammatory bowel disease. Canadian Journal of Gastroenterology and Hepatology, 2016, 5624261. doi:10.1155/2016/5624261.CrossRefPubMedPubMedCentral

60.

Rachmilewitz, D. (1989). Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: A randomised trial. BMJ, 298, 82–86.CrossRefPubMedPubMedCentral

61.

Samuel, S., Bruining, D. H., Loftus Jr, E. V., Thia, K. T., Schroeder, K. W., Tremaine, W. J., et al. (2013). Validation of the ulcerative colitis colonoscopic index of severity and its correlation with disease activity measures. Clinical Gastroenterology Hepatology, 11, 49–54.e1. doi:10.1016/j.cgh.2012.08.003.CrossRefPubMed

62.

Rutgeerts, P. (1989). Comparative efficacy of coated, oral 5-aminosalicylic acid (Claversal*) and sulphasalazine for maintaining remission of ulcerative colitis. Alimentary Pharmacology & Therapeutics, 3, 183–191. doi:10.1111/j.1365-2036.1989.tb00204.x.CrossRef

63.

Iglesias-Rey, M., Barreiro-de Acosta, M., Caamano-Isorna, F., Vazquez Rodriguez, I., Lorenzo Gonzalez, A., Bello-Paderne, X., et al. (2012). Influence of alexithymia on health-related quality of life in inflammatory bowel disease: Are there any related factors? Scandinavian Journal of Gastroenterology, 47, 445–453. doi:10.3109/00365521.2012.654403.CrossRefPubMed

64.

Huppertz-Hauss, G., Lie Hoivik, M., Jelsness-Jorgensen, L., Henriksen, M., Hoie, O., Jahnsen, J., et al. (2016). Health-related quality of life in patients with inflammatory bowel disease 20 years after diagnosis: Results from the IBSEN Study. Inflammatory Bowel Diseases, 22, 1679–1687. doi:10.1097/MIB.0000000000000806.CrossRefPubMed

65.

Boye, B., Lundin, Knut E. A., Leganger, S., Mokleby, K., Jantschek, G., Jantschek, I., et al. (2008). The INSPIRE study: Do personality traits predict general quality of life (Short form-36) in distressed patients with ulcerative colitis and Crohn’s disease? Scandinavian Journal of Gastroenterology, 43, 1505–1513. doi:10.1080/00365520802321196.CrossRefPubMed

66.

Hoivik, M. L., Moum, B., Solberg, I. C., Cvancarova, M., Hoie, O., Vatn, M. H., et al. (2012). Health-related quality of life in patients with ulcerative colitis after a 10-year disease course: Results from the IBSEN study. Inflammatory Bowel Diseases, 18, 1540–1549. doi:10.1002/ibd.21863.CrossRefPubMed

67.

Mokrowiecka, A., Jurek, K., Pinkowski, D., & Malecka-Panas, E. (2006). The comparison of Health-Related Quality of Life (HRQL) in patients with GERD, peptic ulcer disease and ulcerative colitis. Advances in Medical Sciences, 51, 142–147.PubMed

68.

Romberg-Camps, M. J. L., Bol, Y., Dagnelie, P. C., Hesselink-van de Kruijs, M. A. M., Kester, A. D. M., Engels, L. G. J. B., et al. (2010). Fatigue and health-related quality of life in inflammatory bowel disease: Results from a population-based study in the Netherlands: The IBD-South Limburg cohort. Inflammatory Bowel Diseases, 16, 2137–2147. doi:10.1002/ibd.21285.CrossRefPubMed

69.

Gracie, D. J., Williams, C. J. M., Sood, R., Mumtaz, S., Bholah, M. H., Hamlin, P. J., et al. (2017). Negative effects on psychological health and quality of life of genuine irritable bowel syndrome-type symptoms in patients with inflammatory bowel disease. Clinical Gastroenterology and Hepatology, 15, 376.CrossRefPubMed

70.

Ansari, R., Attari, F., Razjouyan, H., Etemadi, A., Amjadi, H., Merat, S., et al. (2008). Ulcerative colitis and irritable bowel syndrome: Relationships with quality of life. European Journal of Gastroenterology and Hepatology, 20, 46–50. doi:10.1097/MEG.0b013e3282f16a62.CrossRefPubMed

71.

Graff, L. A., Walker, J. R., Lix, L., Clara, I., Rawsthorne, P., Rogala, L., et al. (2006). The relationship of inflammatory bowel disease type and activity to psychological functioning and quality of life. Clinical Gastroenterology and Hepatology, 4(1491–1501), e1.

72.

Hjortswang, H., Jarnerot, G., Curman, B., Sandberg-Gertzen, H., Tysk, C., Blomberg, B., et al. (2003). The influence of demographic and disease-related factors on health-related quality of life in patients with ulcerative colitis. European Journal of Gastroenterology and Hepatology, 15, 1011–1020.CrossRefPubMed

73.

Rokke, O., Iversen, K., Olsen, T., Ristesund, S., Eide, G. E., & Turowski, G. E. (2011). Long-term followup of patients with active J-reservoirs after restorative proctocolectomy for ulcerative colitis with regard to reservoir function, mucosal changes, and quality of life. ISRN Gastroenterol., 2011, 430171. doi:10.5402/2011/430171.PubMedPubMedCentral

74.

Tiainen, J., & Matikainen, M. (1999). Health-related quality of life after ileal J-pouch-anal anastomosis for ulcerative colitis: Long-term results. Scandinavian Journal of Gastroenterology, 34, 601–605.CrossRefPubMed

75.

Berndtsson, I., Lindholm, E., Oresland, T., & Borjesson, L. (2007). Long-term outcome after ileal pouch-anal anastomosis: Function and health-related quality of life. Diseases of the Colon and Rectum, 50, 1545–1552. doi:10.1007/s10350-007-0278-6.CrossRefPubMed

76.

Cohen, B. L., Zoega, H., Shah, S. A., Leleiko, N., Lidofsky, S., Bright, R., et al. (2014). Fatigue is highly associated with poor health-related quality of life, disability and depression in newly-diagnosed patients with inflammatory bowel disease, independent of disease activity. Alimentary Pharmacology & Therapeutics, 39, 811–822. doi:10.1111/apt.12659.CrossRef

77.

Koerdt, S., Jehle, E. C., Kreis, M. E., & Kasparek, M. S. (2014). Quality of life after proctocolectomy and ileal pouch-anal anastomosis in patients with ulcerative colitis. International Journal of Colorectal Disease, 29, 545–554.CrossRefPubMed

78.

Palm, O., Bernklev, T., Moum, B., & Gran, J. T. (2005). Non-inflammatory joint pain in patients with inflammatory bowel disease is prevalent and has a significant impact on health related quality of life. Journal of Rheumatology, 32, 1755–1759.PubMed

79.

Thompson-Fawcett, M. W., Richard, C. S., O’Connor, B. I., Cohen, Z., & McLeod, R. S. (2000). Quality of life is excellent after a pelvic pouch for colitis-associated neoplasia. Diseases of the Colon and Rectum, 43, 1497–1502.CrossRefPubMed

80.

Berndtsson, I. E. K., Lindholm, E., Oresland, T., & Hulten, L. (2004). Health-related quality of life and pouch function in continent ileostomy patients: A 30-year perspective 20. Diseases of the Colon and Rectum, 47, 2131–2137.CrossRefPubMed

81.

Jelsness-Jorgensen, L., Bernklev, T., & Moum, B. (2014). Coexisting irritable bowel-like symptoms in inflammatory bowel disease in remission is associated with impaired social functioning and increased bodily pain. Gastroenterology Nursing, 37, 280–287. doi:10.1097/SGA.0000000000000055.CrossRefPubMed

82.

Jelsness-Jorgensen, L., Bernklev, T., Henriksen, M., Torp, R., & Moum, B. A. (2011). Chronic fatigue is associated with impaired health-related quality of life in inflammatory bowel disease. Alimentary Pharmacology & Therapeutics, 33, 106–114. doi:10.1111/j.1365-2036.2010.04498.x.CrossRef

83.

Feagan, B. G., Reinisch, W., Rutgeerts, P., Sandborn, W. J., Yan, S., Eisenberg, D., et al. (2007). The effects of infliximab therapy on health-related quality of life in ulcerative colitis patients. American Journal of Gastroenterology, 102, 794–802. doi:10.1111/j.1572-0241.2007.01094.x.CrossRefPubMed

84.

Therkelsen, S. P., Hetland, G., Lyberg, T., Lygren, I., & Johnson, E. (2016). Effect of a medicinal Agaricus blazei Murill-based mushroom extract, AndoSan™, on symptoms, fatigue and quality of life in patients with ulcerative colitis in a randomized single-blinded placebo controlled study. PLoS ONE, 11, e0150191. doi:10.1371/journal.pone.0150191.CrossRefPubMedPubMedCentral

85.

Feagan, B. G., Patel, H., Colombel, J., Rubin, D. T., James, A., Mody, R., et al. (2017). Effects of vedolizumab on health-related quality of life in patients with ulcerative colitis: Results from the randomised GEMINI 1 trial. Alimentary Pharmacology & Therapeutics, 45, 264–275. doi:10.1111/apt.13852.CrossRef

86.

Dai, Y., Zheng, L., Zhang, Y., Chen, X., Chen, D., & Tang, Z. (2017). Effects of Jianpi Qingchang decoction on the quality of life of patients with ulcerative colitis: A randomized controlled trial. Medicine (Baltimore), 96, e6651. doi:10.1097/MD.0000000000006651.CrossRef

87.

Elsenbruch, S., Langhorst, J., Popkirowa, K., Muller, T., Luedtke, R., Franken, U., et al. (2005). Effects of mind-body therapy on quality of life and neuroendocrine and cellular immune functions in patients with ulcerative colitis. Psychotherapy and Psychosomatics, 74, 277–287. doi:10.1159/000086318.CrossRefPubMed

88.

Reinisch, W., Sandborn, W. J., Bala, M., Yan, S., Feagan, B. G., Rutgeerts, P., et al. (2007). Response and remission are associated with improved quality of life, employment and disability status, hours worked, and productivity of patients with ulcerative colitis. Inflammatory Bowel Diseases, 13, 1135–1140. doi:10.1002/ibd.20165.CrossRefPubMed

89.

Heikens, J. T., de Vries, J., Goos, M. R. E., Oostvogel, H. J., Gooszen, H. G., & van Laarhoven, C. J. H. M. (2012). Quality of life and health status before and after ileal pouch-anal anastomosis for ulcerative colitis. British Journal of Surgery, 99, 263–269. doi:10.1002/bjs.7711.CrossRefPubMed

90.

Muir, A. J., Edwards, L. J., Sanders, L. L., Bollinger, R. R., Koruda, M. J., Bachwich, D. R., et al. (2001). A prospective evaluation of health-related quality of life after ileal pouch anal anastomosis for ulcerative colitis. American Journal of Gastroenterology, 96, 1480–1485. doi:10.1111/j.1572-0241.2001.03801.x.CrossRefPubMed

91.

Bastida, G., Nos, P., Aguas, M., Beltran, B., Iborra, M., Ortiz, V., et al. (2010). The effects of thiopurine therapy on health-related quality of life in Inflammatory Bowel Disease patients. BMC Gastroenterol., 10, 26. doi:10.1186/1471-230X-10-26.CrossRefPubMedPubMedCentral

92.

Cekic, C., Ipek, S., Aslan, F., Akpinar, Z., Arabul, M., Topal, F., et al. (2015). The effect of intravenous iron treatment on quality of life in inflammatory bowel disease patients with nonanemic iron deficiency. Gastroenterology Research Practice, 2015, 582163. doi:10.1155/2015/582163.PubMedPubMedCentral

93.

Tulchinsky, H., Dotan, I., Halpern, Z., Klausner, J. M., & Rabau, M. (2010). A longitudinal study of quality of life and functional outcome of patients with ulcerative colitis after proctocolectomy with ileal pouch-anal anastomosis. Diseases of the Colon and Rectum, 53, 866–873. doi:10.1007/DCR.0b013e3181d98d66.CrossRefPubMed

94.

Jelsness-Jorgensen, L., Bernklev, T., Henriksen, M., Torp, R., & Moum, B. (2012). Is patient reported outcome (PRO) affected by different follow-up regimens in inflammatory bowel disease (IBD)? A one year prospective, longitudinal comparison of nurse-led versus conventional follow-up. J Crohns Colitis., 6, 887–894. doi:10.1016/j.crohns.2012.01.021.CrossRefPubMed

95.

Ware, J. E., Kosinski, M., Gandek, B., Aaronson, N. K., Apolone, G., Bech, P., et al. (1998). The factor structure of the SF-36 Health Survey in 10 countries: Results from the IQOLA Project. International Quality of Life Assessment. Journal of Clinical Epidemiology, 51, 1159–1165.CrossRefPubMed

96.

McHorney, C. A., Ware, J. E., Lu, J. F., & Sherbourne, C. D. (1994). The MOS 36-item Short-Form Health Survey (SF-36): III. Tests of data quality, scaling assumptions, and reliability across diverse patient groups. Medical Care, 32, 40–66.CrossRefPubMed

97.

Gandek, B., Sinclair, S. J., Kosinski, M., & Ware, J. E. (2004). Psychometric evaluation of the SF-36 health survey in Medicare managed care. Health Care Financ Rev., 25, 5–25.PubMedPubMedCentral

98.

White, M. K., Yarlas, A., Ingham, M., & Han, C. (2016). Cognitive debriefing of the SF-36v2 with moderate-to-severe Crohn’s disease patients. Value Health., 19, A316. doi:10.1016/j.jval.2016.03.964.CrossRef

Titel: Psychometric validation of the SF-36® Health Survey in ulcerative colitis: results from a systematic literature review
verfasst von: Aaron Yarlas
Martha Bayliss
Joseph C. Cappelleri
Stephen Maher
Andrew G. Bushmakin
Lea Ann Chen
Alireza Manuchehri
Paul Healey
Publikationsdatum: 28.08.2017
Verlag: Springer International Publishing
Erschienen in: Quality of Life Research / Ausgabe 2/2018
Print ISSN: 0962-9343
Elektronische ISSN: 1573-2649
DOI: https://doi.org/10.1007/s11136-017-1690-6

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Psychometric validation of the SF-36^® Health Survey in ulcerative colitis: results from a systematic literature review

Abstract

Purpose

Methods

Results

Conclusions

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2018

Associated and mediating variables related to quality of life among service users with mental disorders

International development of four EORTC disease-specific quality of life questionnaires for patients with Hodgkin lymphoma, high- and low-grade non-Hodgkin lymphoma and chronic lymphocytic leukaemia

Evidence on the longitudinal construct validity of major generic and utility measures of health-related quality of life in teens with depression

Clustering based on unsupervised binary trees to define subgroups of cancer patients according to symptom severity in cancer

An evaluation of the structural validity of the shoulder pain and disability index (SPADI) using the Rasch model

The Minneapolis-Manchester Quality of Life Instrument: reliability and validity of the Adult Form in cancer survivors